Published Jul 14, 2023
Nvidia Invests $50M into AI Drug Discovery Firm Recursion
Delve into Nvidia's $50 million investment in AI drug discovery firm Recursion, a strategic maneuver that enhances Nvidia's AI ecosystem and aims to revolutionize pharmaceutical research, driving AI advancements and positioning both companies for a future of groundbreaking medical innovations.
Topics covered
Popular Clips
Episode Highlights
Related Episodes
Nvidia's Generative AI for Robotics
Answers 383 questionsNvidia Passes $1T Market Cap with Explosive AI Product Launch
Answers 383 questionsGoogle Invests $2B into Anthropic: AI Funding Heats up
Answers 383 questionsNvidia's AI GPUs Propel 233% Q2 Growth Forecast, Stock Soars
Answers 383 questionsVisa Announces Plan to Invest $100M into Generative AI Companies
Answers 383 questionsNvidia Announces Text to Video AI Generation
Answers 383 questions$10B+ in AI Deals Announced in Q1 2023, Which Corporations are Investing the Most?
Answers 383 questionsWhy OpenAI is Investing $100M in AI Startups
Answers 383 questionsChina's Tech Giants' $340M Investment in OpenAI Rival
Answers 383 questionsNvidia CEO Delivers 1st DGX H200 to OpenAI
Answers 383 questionsDatabricks Raises $500M at $43B Valuation from Nvidia and Capital One
Answers 383 questionsElon's xAI Raises $6B, to do R&D for Tesla and SpaceX
Answers 383 questionsDeepSeek Threatening Nvidia: US Gov Responds
Answers 383 questionsGoogle Eyeing Investment in Character.ai
Answers 383 questions